NEW YORK (GenomeWeb News) – Nasdaq has granted CombiMatrix an extension to provide evidence that it is in compliance with a listing requirement, the company said in a regulatory document on Thursday.

In a filing with the US Securities and Exchange Commission, CombiMatrix said that Nasdaq has given it until Aug. 20 to provide evidence in its Form 10-Q for the second quarter ending June 30 that it complies with a rule calling for at least $2.5 million in stockholders' equity in order to remain listed on the exchange.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.